another interesting study indicating that the new oral anti-coagulants such as apixaban have a lower risk of major bleeding issues than products such as warfarin. however there are some caveats:
"The researchers point out that this is an observational study, so no firm conclusions can be drawn about cause and effect, and they outline some limitations, such as possible misclassification due to patients not taking their medication."
and from the BMJ:
"Overall, apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were, however, associated with increased risks of all cause mortality compared with warfarin."
medicalxpress.com/news/2018...
full BMJ paper here